Substance / Medication

Loteprednol

Overview

Active Ingredient
loteprednol
RxNorm CUI
237027

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

31 trials linked to this intervention

31
Total Trials
2
Recruiting
17
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and Safety of Loteprednol Etabonate in Managing Pain and Inflammation After Cataract Surgery: A Systematic Review and Meta-analysis.
Elettreby Abdelrahman M, Alsaied Mohamed A, Saleh Maab M et al. · Eye Contact Lens · 2025
PMID: 40830916Meta-Analysis
Loteprednol etabonate in the treatment of allergic conjunctivitis: a meta-analysis.
Wu Lian-Qun, Chen Xu, Lou Heng et al. · Curr Med Res Opin · 2015
PMID: 26039179Meta-Analysis
Clinical efficacy of Fluorometholone versus Loteprednol eye drops after photorefractive keratectomy: A triple-blinded randomized controlled trial.
Razmjoo Hasan, Mikaniki Mohammad, Peyman Alireza et al. · Eur J Ophthalmol · 2023
PMID: 35656757RCT
Comparison of 2 regimens of loteprednol etabonate and bromfenac for cataract surgery.
Al-Awadi Ahmad, Tokko Hassan A, Chan Clara C et al. · Can J Ophthalmol · 2019
PMID: 31109481RCT
Comparison of Efficacy and Safety of Loteprednol Etabonate 0.5% and Topical Dexamethasone 1% in Post-Vitrectomy Inflammation.
Bilgin Ahmet Burak, Dogan Mehmet Erkan, Ayaz Yusuf et al. · Ocul Immunol Inflamm · 2019
PMID: 29283786RCT
A randomized controlled trial comparing dexamethasone with loteprednol etabonate on postoperative photorefractive keratectomy.
Thanathanee Onsiri, Sriphon Phornrak, Anutarapongpan Orapin et al. · J Ocul Pharmacol Ther · 2015
PMID: 25555173RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Loteprednol (substance)
SNOMED CT
419711001
UMLS CUI
C0772364
RxNorm CUI
237027

Clinical Data

This intervention maps to 9 entities in the Healos knowledge graph.

9
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
31
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.